Literature DB >> 11880515

The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease.

Marcus A Westerman1, Deirdre Cooper-Blacketer, Ami Mariash, Linda Kotilinek, Takeshi Kawarabayashi, Linda H Younkin, George A Carlson, Steven G Younkin, Karen H Ashe.   

Abstract

Transgenic mice expressing mutant amyloid precursor proteins (APPs) have provided important new information about the pathogenesis of Alzheimer's disease (AD) histopathology. However, the molecular basis of memory loss in these mice is poorly understood. One of the major impediments has been the difficulty of distinguishing between age-dependent and age-independent behavioral changes. To address this issue we studied in parallel two lines of APP transgenic mice expressing comparable levels of mutant and wild-type human APP. This enabled us to identify age-independent behavioral deficits that were not specifically related to mutant APP expression. When mice with age-independent deficits were eliminated, we detected memory loss in transgenic mice expressing mutant APP (Tg2576 mice) starting at approximately 6 months, which coincided with the appearance of detergent-insoluble Abeta aggregates (Abeta(insol)). Genetically accelerating the formation of Abeta(insol) resulted in an earlier onset of memory decline. A facile interpretation of these results, namely that memory loss and Abeta(insol) were closely connected, was rejected when we extended our analysis to include older mice. No obvious correspondence between memory and Abeta(insol) was apparent in a combined group of old and young mice unless the mice were stratified by age, whereupon inverse correlations between memory and Abeta(insol) became evident. These results suggested that Abeta(insol) is a surrogate marker for small assemblies of Abeta that disrupt cognition and occur as intermediates during Abeta(insol) formation, and they are the first descriptive in vivo data supporting their role in impairing memory. These studies also provide a methodological framework within which to investigate these Abeta assemblies in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11880515      PMCID: PMC6758862     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  49 in total

1.  Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long-term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway.

Authors:  M E Bach; M Barad; H Son; M Zhuo; Y F Lu; R Shih; I Mansuy; R D Hawkins; E R Kandel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

2.  Purification and cloning of amyloid precursor protein beta-secretase from human brain.

Authors:  S Sinha; J P Anderson; R Barbour; G S Basi; R Caccavello; D Davis; M Doan; H F Dovey; N Frigon; J Hong; K Jacobson-Croak; N Jewett; P Keim; J Knops; I Lieberburg; M Power; H Tan; G Tatsuno; J Tung; D Schenk; P Seubert; S M Suomensaari; S Wang; D Walker; J Zhao; L McConlogue; V John
Journal:  Nature       Date:  1999-12-02       Impact factor: 49.962

3.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

4.  Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease.

Authors:  K Johnson-Wood; M Lee; R Motter; K Hu; G Gordon; R Barbour; K Khan; M Gordon; H Tan; D Games; I Lieberburg; D Schenk; P Seubert; L McConlogue
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

5.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Authors:  M P Lambert; A K Barlow; B A Chromy; C Edwards; R Freed; M Liosatos; T E Morgan; I Rozovsky; B Trommer; K L Viola; P Wals; C Zhang; C E Finch; G A Krafft; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

6.  Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits.

Authors:  L A Holcomb; M N Gordon; P Jantzen; K Hsiao; K Duff; D Morgan
Journal:  Behav Genet       Date:  1999-05       Impact factor: 2.805

7.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.

Authors:  R Vassar; B D Bennett; S Babu-Khan; S Kahn; E A Mendiaz; P Denis; D B Teplow; S Ross; P Amarante; R Loeloff; Y Luo; S Fisher; J Fuller; S Edenson; J Lile; M A Jarosinski; A L Biere; E Curran; T Burgess; J C Louis; F Collins; J Treanor; G Rogers; M Citron
Journal:  Science       Date:  1999-10-22       Impact factor: 47.728

8.  High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation.

Authors:  L Mucke; E Masliah; G Q Yu; M Mallory; E M Rockenstein; G Tatsuno; K Hu; D Kholodenko; K Johnson-Wood; L McConlogue
Journal:  J Neurosci       Date:  2000-06-01       Impact factor: 6.167

9.  Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43).

Authors:  S A Gravina; L Ho; C B Eckman; K E Long; L Otvos; L H Younkin; N Suzuki; S G Younkin
Journal:  J Biol Chem       Date:  1995-03-31       Impact factor: 5.157

10.  An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants.

Authors:  N Suzuki; T T Cheung; X D Cai; A Odaka; L Otvos; C Eckman; T E Golde; S G Younkin
Journal:  Science       Date:  1994-05-27       Impact factor: 47.728

View more
  244 in total

1.  An improved method for generating consistent soluble amyloid-beta oligomer preparations for in vitro neurotoxicity studies.

Authors:  Deborah A Ryan; Wade C Narrow; Howard J Federoff; William J Bowers
Journal:  J Neurosci Methods       Date:  2010-05-07       Impact factor: 2.390

Review 2.  Mouse models of Alzheimer's disease.

Authors:  Alicia M Hall; Erik D Roberson
Journal:  Brain Res Bull       Date:  2011-11-28       Impact factor: 4.077

Review 3.  Alzheimer's therapeutics: translation of preclinical science to clinical drug development.

Authors:  Alena V Savonenko; Tatiana Melnikova; Andrew Hiatt; Tong Li; Paul F Worley; Juan C Troncoso; Phil C Wong; Don L Price
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

Review 4.  Usefulness of behavioral and electrophysiological studies in transgenic models of Alzheimer's disease.

Authors:  Antonino Sant'Angelo; Fabrizio Trinchese; Ottavio Arancio
Journal:  Neurochem Res       Date:  2003-07       Impact factor: 3.996

5.  Molecular dynamics simulation of amyloid beta dimer formation.

Authors:  B Urbanc; L Cruz; F Ding; D Sammond; S Khare; S V Buldyrev; H E Stanley; N V Dokholyan
Journal:  Biophys J       Date:  2004-10       Impact factor: 4.033

Review 6.  Genetic animal models of cerebral vasculopathies.

Authors:  Jeong Hyun Lee; Brian J Bacskai; Cenk Ayata
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

Review 7.  APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD).

Authors:  R Lalonde; K Fukuchi; C Strazielle
Journal:  Neurosci Biobehav Rev       Date:  2012-02-21       Impact factor: 8.989

8.  Combination therapy with octyl gallate and ferulic acid improves cognition and neurodegeneration in a transgenic mouse model of Alzheimer's disease.

Authors:  Takashi Mori; Naoki Koyama; Jun Tan; Tatsuya Segawa; Masahiro Maeda; Terrence Town
Journal:  J Biol Chem       Date:  2017-05-16       Impact factor: 5.157

9.  Reduced CXCL12/CXCR4 results in impaired learning and is downregulated in a mouse model of Alzheimer disease.

Authors:  A Parachikova; C W Cotman
Journal:  Neurobiol Dis       Date:  2007-07-10       Impact factor: 5.996

10.  Enhanced cognitive activity--over and above social or physical activity--is required to protect Alzheimer's mice against cognitive impairment, reduce Abeta deposition, and increase synaptic immunoreactivity.

Authors:  Jennifer R Cracchiolo; Takashi Mori; Stanley J Nazian; Jun Tan; Huntington Potter; Gary W Arendash
Journal:  Neurobiol Learn Mem       Date:  2007-08-21       Impact factor: 2.877

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.